The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides.

Three chemokines, Mig, IP-10, and I-TAC, are expressed highly in the epidermis. We examined the expression of the receptor for these chemokines, CXCR3, in cutaneous T-cell lymphoma. We compared CXCR3 expression with that of cutaneous lymphocyte antigen (CLA) and the activation marker CD30. CXCR3 was expressed by at least a subset of tumor lymphocytes in all 25 cases of low-grade mycosis fungoides (MF), with most cells positive in 20 cases. In progressed or transformed MF, CXCR3 expression was noted in 5 of 22 cases. In 4 of 5 MF cases with sequential biopsy specimens, large cell transformation was accompanied by loss of CXCR3 expression. In contrast, CLA was expressed in 35 of 42 MF cases with no significant differences in expression level between low-grade and transformed cases. In other lymphomas, CXCR3 was expressed in 4 of 4 cases of lymphomatoid papulosis, 3 of 4 cases of CD8+ cutaneous T-cell lymphoma, and 3 of 6 cases of systemic T-cell lymphoma in skin, but not in 10 cases of cutaneous anaplastic large cell lymphoma. CXCR3 expression was associated with epidermotropic T-cell tumors but was largely absent in dermal-based tumors. This phenotypic change likely influences the loss of epidermal localization.

[1]  D. Dorfman,et al.  Recurrences in nodal T-cell lymphoma. Changes in histologic appearance and immunophenotype over the course of disease. , 2000, American journal of clinical pathology.

[2]  D. Dorfman,et al.  Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. , 2000, Blood.

[3]  M. Piris,et al.  p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides. , 2000, The American journal of pathology.

[4]  Weiqi Wang,et al.  Cutting Edge: The Orphan Chemokine Receptor G Protein-Coupled Receptor-2 (GPR-2, CCR10) Binds the Skin-Associated Chemokine CCL27 (CTACK/ALP/ILC)1 , 2000, The Journal of Immunology.

[5]  Yu Wang,et al.  Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell- and T Cell-Active Chemokines Including ELC, SLC, and TECK , 2000, The Journal of Immunology.

[6]  D. Dorfman,et al.  The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. , 2000, Blood.

[7]  N. Copeland,et al.  CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Nibbs,et al.  ESkine, a Novel β-Chemokine, Is Differentially Spliced to Produce Secretable and Nuclear Targeted Isoforms* , 1999, The Journal of Biological Chemistry.

[9]  R. Suzuki,et al.  Molecular cloning of a novel CC chemokine, interleukin‐11 receptor α‐locus chemokine (ILC), which is located on chromosome 9p13 and a potential homologue of a CC chemokine encoded by molluscum contagiosum virus , 1999, FEBS letters.

[10]  J. Flier,et al.  The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. , 1999, The Journal of investigative dermatology.

[11]  James J. Campbell,et al.  The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells , 1999, Nature.

[12]  L. Trentin,et al.  The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. , 1999, The Journal of clinical investigation.

[13]  J. Flier,et al.  IP-10 mRNA expression in cultured keratinocytes is suppressed by inhibition of protein kinase-C and tyrosine kinase and elevation of cAMP. , 1999, Cytokine.

[14]  R. Hromas,et al.  Isolation of ALP, a novel divergent murine CC chemokine with a unique carboxy terminal extension. , 1999, Biochemical and biophysical research communications.

[15]  R. Leurs,et al.  Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). , 1999, The Journal of investigative dermatology.

[16]  C. Meijer,et al.  Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease. , 1999, The American journal of pathology.

[17]  Z. Estrov,et al.  Dysregulated Synthesis of Intracellular Type 1 and Type 2 Cytokines by T Cells of Patients with Cutaneous T-Cell Lymphoma , 1999, Clinical Diagnostic Laboratory Immunology.

[18]  R. Kurzrock,et al.  Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. , 1998, Blood.

[19]  P. V. Stoop,et al.  Epidermal Interferon-γ Inducible Protein-10 (IP-10) and Monokine Induced by γ-Interferon (Mig) but not IL-8 mRNA Expression is Associated with Epidermotropism in Cutaneous T Cell Lymphomas , 1998 .

[20]  C. Felix,et al.  Overexpression of p53 protein in cutaneous T cell lymphoma: relationship to large cell transformation and disease progression. , 1998, The Journal of investigative dermatology.

[21]  C. Mackay,et al.  Flexible Programs of Chemokine Receptor Expression on Human Polarized T Helper 1 and 2 Lymphocytes , 1998, The Journal of experimental medicine.

[22]  C. Mackay,et al.  The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. , 1998, The Journal of clinical investigation.

[23]  D. Steiner,et al.  Cloning, expression, and chromosomal mapping of a novel human CC-chemokine receptor (CCR10) that displays high-affinity binding for MCP-1 and MCP-3. , 1997, DNA and cell biology.

[24]  R. Martí,et al.  T-cell population of primary and secondary cutaneous B-cell lymphomas does not express the cutaneous lymphocyte-associated antigen (CLA) , 1997, Archives of Dermatological Research.

[25]  A. Zelenetz,et al.  Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  A. Deisseroth,et al.  Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma? , 1995, Blood.

[27]  M. Bagot,et al.  Cutaneous T-cell infiltrates: analysis of T-cell receptor gamma gene rearrangement by polymerase chain reaction and denaturing gradient gel electrophoresis. , 1995, Blood.

[28]  P. E. Shapiro,et al.  The Histologic Spectrum of Mycosis Fungoides/Sézary Syndrome (Cutaneous T‐Cell Lymphoma): A Review of 222 Biopsies, Including Newly Described Patterns and the Earliest Pathologic Changes , 1994, The American journal of surgical pathology.

[29]  P. Heerde,et al.  Differential expression of the HECA‐452 antigen (cutaneous lymphocyte associated antigen, CLA) in cutaneous and non‐cutaneous T‐cell lymphomas , 1992, Histopathology.

[30]  M. Kadin.  Lymphomatoid papulosis, Ki-1+ lymphoma, and primary cutaneous Hodgkin's disease. , 1991, Seminars in dermatology.

[31]  L. King,et al.  Clinical features associated with transformation of cerebriform T‐cell lymphoma to a large cell process , 1990, Hematological oncology.

[32]  J. Greer,et al.  Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. , 1988, The American journal of pathology.

[33]  J. Ravetch,et al.  Biochemical characterization of a gamma interferon-inducible cytokine (IP-10) , 1987, The Journal of experimental medicine.

[34]  M. Reiss,et al.  Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas. , 1996, Leukemia & lymphoma.